Xellia pays steep price for factory delays

Novo company Xellia Pharmaceuticals has not generated the profits which it had hoped for and instead presents a notable deficit for 2020. The firm blames competitive prices and factory issues.

Photo: Xellia Pharmaceuticals / PR

Following last year's record profit, Xellia Pharmaceuticals seemed to have started a new growth spurt, but this did not turn out to be the case. Danish media Børsen reports that instead, the firm reports a DKK 133m (USD 21.8m) deficit for 2020 compared to its DKK 400m profit in 2019.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs